Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents

Qiu Jie Jiang, Jan Izakovic, Martin Zenker, Manige Fartasch, Guerrino Meneguzzi, Wolfgang Rascher, Holm Schneider

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To evaluate the effects of a treatment with artificial skin bioequivalents in Herlitz junctional epidermolysis bullosa (H-JEB). Methods: Two infants, both homozygous for the Herlitz mutation R635X in the LAMB3 gene, who had refractory anemia and hypoproteinemia as a result of a continuous loss of body fluids through multiple large erosions, were treated with artificial skin bioequivalents. Results: In the first patient, 10 of 13 acute or chronic wounds were found healed 3 to 6 weeks after the treatment, and the protein, iron, and hemoglobin levels normalized. Normal weight gain and marked improvement of the quality of life for this patient's family have been evident since. Nine treated wounds remained healed for at least 18 weeks and appeared to be more resistant to trauma. In a skin biopsy from a treated site obtained after 9 weeks, DNA of the graft was still detectable by polymerase chain reaction. In the second patient, who was treated at a late stage of the disease, only 2 of 18 chronic wounds were found healed at 3 weeks after the treatment. One site remained healed completely, and some additional islets of the grafts persisted for longer. There were no adverse events. Conclusion: Early treatment with artificial skin substitutes may improve the clinical course of H-JEB. However, a true cure of the cutaneous manifestations of H-JEB would require gene therapy of autologous epidermal stem cells, which could then be transplanted by using this or a similar cultured skin bioequivalent.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalJournal of Pediatrics
Volume141
Issue number4
DOIs
StatePublished - Oct 1 2002

Fingerprint

Junctional Epidermolysis Bullosa
Artificial Skin
Wounds and Injuries
Refractory Anemia
Hypoproteinemia
Transplants
Skin Manifestations
Skin
Body Fluids
Therapeutics
Genetic Therapy
Weight Gain
Hemoglobins
Stem Cells
Iron
Quality of Life
Biopsy
Polymerase Chain Reaction
Mutation
DNA

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Jiang, Q. J., Izakovic, J., Zenker, M., Fartasch, M., Meneguzzi, G., Rascher, W., & Schneider, H. (2002). Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents. Journal of Pediatrics, 141(4), 553-559. https://doi.org/10.1067/mpd.2002.127794

Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents. / Jiang, Qiu Jie; Izakovic, Jan; Zenker, Martin; Fartasch, Manige; Meneguzzi, Guerrino; Rascher, Wolfgang; Schneider, Holm.

In: Journal of Pediatrics, Vol. 141, No. 4, 01.10.2002, p. 553-559.

Research output: Contribution to journalArticle

Jiang, QJ, Izakovic, J, Zenker, M, Fartasch, M, Meneguzzi, G, Rascher, W & Schneider, H 2002, 'Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents', Journal of Pediatrics, vol. 141, no. 4, pp. 553-559. https://doi.org/10.1067/mpd.2002.127794
Jiang, Qiu Jie ; Izakovic, Jan ; Zenker, Martin ; Fartasch, Manige ; Meneguzzi, Guerrino ; Rascher, Wolfgang ; Schneider, Holm. / Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents. In: Journal of Pediatrics. 2002 ; Vol. 141, No. 4. pp. 553-559.
@article{d280252d623b4906af4cab0ad5556031,
title = "Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents",
abstract = "Objective: To evaluate the effects of a treatment with artificial skin bioequivalents in Herlitz junctional epidermolysis bullosa (H-JEB). Methods: Two infants, both homozygous for the Herlitz mutation R635X in the LAMB3 gene, who had refractory anemia and hypoproteinemia as a result of a continuous loss of body fluids through multiple large erosions, were treated with artificial skin bioequivalents. Results: In the first patient, 10 of 13 acute or chronic wounds were found healed 3 to 6 weeks after the treatment, and the protein, iron, and hemoglobin levels normalized. Normal weight gain and marked improvement of the quality of life for this patient's family have been evident since. Nine treated wounds remained healed for at least 18 weeks and appeared to be more resistant to trauma. In a skin biopsy from a treated site obtained after 9 weeks, DNA of the graft was still detectable by polymerase chain reaction. In the second patient, who was treated at a late stage of the disease, only 2 of 18 chronic wounds were found healed at 3 weeks after the treatment. One site remained healed completely, and some additional islets of the grafts persisted for longer. There were no adverse events. Conclusion: Early treatment with artificial skin substitutes may improve the clinical course of H-JEB. However, a true cure of the cutaneous manifestations of H-JEB would require gene therapy of autologous epidermal stem cells, which could then be transplanted by using this or a similar cultured skin bioequivalent.",
author = "Jiang, {Qiu Jie} and Jan Izakovic and Martin Zenker and Manige Fartasch and Guerrino Meneguzzi and Wolfgang Rascher and Holm Schneider",
year = "2002",
month = "10",
day = "1",
doi = "10.1067/mpd.2002.127794",
language = "English",
volume = "141",
pages = "553--559",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents

AU - Jiang, Qiu Jie

AU - Izakovic, Jan

AU - Zenker, Martin

AU - Fartasch, Manige

AU - Meneguzzi, Guerrino

AU - Rascher, Wolfgang

AU - Schneider, Holm

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Objective: To evaluate the effects of a treatment with artificial skin bioequivalents in Herlitz junctional epidermolysis bullosa (H-JEB). Methods: Two infants, both homozygous for the Herlitz mutation R635X in the LAMB3 gene, who had refractory anemia and hypoproteinemia as a result of a continuous loss of body fluids through multiple large erosions, were treated with artificial skin bioequivalents. Results: In the first patient, 10 of 13 acute or chronic wounds were found healed 3 to 6 weeks after the treatment, and the protein, iron, and hemoglobin levels normalized. Normal weight gain and marked improvement of the quality of life for this patient's family have been evident since. Nine treated wounds remained healed for at least 18 weeks and appeared to be more resistant to trauma. In a skin biopsy from a treated site obtained after 9 weeks, DNA of the graft was still detectable by polymerase chain reaction. In the second patient, who was treated at a late stage of the disease, only 2 of 18 chronic wounds were found healed at 3 weeks after the treatment. One site remained healed completely, and some additional islets of the grafts persisted for longer. There were no adverse events. Conclusion: Early treatment with artificial skin substitutes may improve the clinical course of H-JEB. However, a true cure of the cutaneous manifestations of H-JEB would require gene therapy of autologous epidermal stem cells, which could then be transplanted by using this or a similar cultured skin bioequivalent.

AB - Objective: To evaluate the effects of a treatment with artificial skin bioequivalents in Herlitz junctional epidermolysis bullosa (H-JEB). Methods: Two infants, both homozygous for the Herlitz mutation R635X in the LAMB3 gene, who had refractory anemia and hypoproteinemia as a result of a continuous loss of body fluids through multiple large erosions, were treated with artificial skin bioequivalents. Results: In the first patient, 10 of 13 acute or chronic wounds were found healed 3 to 6 weeks after the treatment, and the protein, iron, and hemoglobin levels normalized. Normal weight gain and marked improvement of the quality of life for this patient's family have been evident since. Nine treated wounds remained healed for at least 18 weeks and appeared to be more resistant to trauma. In a skin biopsy from a treated site obtained after 9 weeks, DNA of the graft was still detectable by polymerase chain reaction. In the second patient, who was treated at a late stage of the disease, only 2 of 18 chronic wounds were found healed at 3 weeks after the treatment. One site remained healed completely, and some additional islets of the grafts persisted for longer. There were no adverse events. Conclusion: Early treatment with artificial skin substitutes may improve the clinical course of H-JEB. However, a true cure of the cutaneous manifestations of H-JEB would require gene therapy of autologous epidermal stem cells, which could then be transplanted by using this or a similar cultured skin bioequivalent.

UR - http://www.scopus.com/inward/record.url?scp=0036799273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036799273&partnerID=8YFLogxK

U2 - 10.1067/mpd.2002.127794

DO - 10.1067/mpd.2002.127794

M3 - Article

C2 - 12378197

AN - SCOPUS:0036799273

VL - 141

SP - 553

EP - 559

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -